TP53 mutation + KRAS mutation
|
NSCLC
|
TP53 mutation + KRAS mutation
|
NSCLC
|
Immunotherapy Sensitive: B - Late Trials
|
Immunotherapy Sensitive: B - Late Trials
|
TP53 mutation + KRAS mutation
|
LUAD
|
TP53 mutation + KRAS mutation
|
LUAD
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
TP53 mutation + KRAS mutation
|
LUAD
|
TP53 mutation + KRAS mutation
|
LUAD
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
TP53 mutation + KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
TP53 mutation + KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
TP53 mutation + KRAS mutation
|
Colon Cancer
|
TP53 mutation + KRAS mutation
|
Colon Cancer
|
LY 2603618 Sensitive: D – Preclinical
|
LY 2603618 Sensitive: D – Preclinical
|